MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
103.78
+0.11
+0.11%
After Hours: 103.78 0 0.00% 16:10 04/02 EDT
OPEN
101.59
PREV CLOSE
103.67
HIGH
104.31
LOW
101.59
VOLUME
601.60K
TURNOVER
--
52 WEEK HIGH
107.84
52 WEEK LOW
39.60
MARKET CAP
6.62B
P/E (TTM)
-50.6936
1D
5D
1M
3M
1Y
5Y
1D
XSMO, ESE, KRYS, PTGX: ETF Outflow Alert
NASDAQ · 3d ago
Weekly Report: what happened at PTGX last week (0323-0327)?
Weekly Report · 6d ago
Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program
Benzinga · 6d ago
Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance
Reuters · 03/28 14:05
Protagonist Therapeutics Executives Quietly Cash In on Major Insider Stock Sales
TipRanks · 03/28 02:02
Protagonist Therapeutics; Chief Medical Officer Arturo Molina disposes of 15,000 common shares valued at $1,572,000
Reuters · 03/27 23:36
Protagonist Therapeutics director Harold E. Selick disposes of 24,000 common shares; value drops to $2,520,000
Reuters · 03/27 23:35
Protagonist Therapeutics CFO Ali Asif disposes of common shares; sale totals $2,581,000
Reuters · 03/27 23:34
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.